CAJ | 학술논문

目的：观察含伊立替康的联合化疗方案在晚期食管癌二线治疗中的临床疗效及毒性反应。方法35例既往经紫杉醇联合铂类一线化疗无效或进展的晚期食管癌患者,二线化疗使用伊立替康+顺铂方案20例(伊立替康180 mg/m2静滴第1天,顺铂50 mg/m2静滴第2天)；使用伊立替康+氟尿嘧啶+亚叶酸钙(FOLFIRI)方案15例(伊立替康180 mg/m2静滴第1天,氟尿嘧啶2400 mg/m2持续静滴46 h,亚叶酸钙400 mg/m2静滴第1天),均为双周化疗方案。结果完全缓解(CR)0例,部分缓解(PR)8例,稳定(SD)12例,进展(PD)15例,有效率为22.8%,疾病控制率为57.1%,中位无进展生存期(PFS)2.7个月,中位总生存期(OS)7.3个月。主要毒副反应为血液学毒性及恶心呕吐、腹泻,全组无毒性相关死亡。结论含伊立替康的联合化疗方案作为晚期食管癌的二线治疗方案安全有效,毒副反应可耐受,值得在临床上进一步观察及研究。
목적：관찰함이립체강적연합화료방안재만기식관암이선치료중적림상료효급독성반응。방법35례기왕경자삼순연합박류일선화료무효혹진전적만기식관암환자,이선화료사용이립체강+순박방안20례(이립체강180 mg/m2정적제1천,순박50 mg/m2정적제2천)；사용이립체강+불뇨밀정+아협산개(FOLFIRI)방안15례(이립체강180 mg/m2정적제1천,불뇨밀정2400 mg/m2지속정적46 h,아협산개400 mg/m2정적제1천),균위쌍주화료방안。결과완전완해(CR)0례,부분완해(PR)8례,은정(SD)12례,진전(PD)15례,유효솔위22.8%,질병공제솔위57.1%,중위무진전생존기(PFS)2.7개월,중위총생존기(OS)7.3개월。주요독부반응위혈액학독성급악심구토、복사,전조무독성상관사망。결론함이립체강적연합화료방안작위만기식관암적이선치료방안안전유효,독부반응가내수,치득재림상상진일보관찰급연구。
Objective To evaluate the efficacy and toxicity of irinotecan (CPT-1 1 )as second-line regimens in patients with advanced esophageal squamous cell carcinoma (ESCC).Methods A total of 35 advanced ESCC patients after failure to chemotherapy with paclitaxel and platinum received Irinotecan-based combination chemotherapy as second-line regimen.Of them,20 cases received IP regimen (irinotecan 180 mg/m2 d1,cisplatin 50 mg/m2 d2),15 cases received FOLFIRI regimen (irinotecan 180 mg/m2 d1,5-FU 2 400 mg/m2 continuous infusion over 46 hours,folinic acid (FA)400 mg/m2 d1),all re-peated every 14 days.Results For a total of 35 patients,8 patients achieved PR,12 patients achieved SD,15 patients a-chieved PD.The response rate was 22.8%,and the disease control rate was 57.1%.The median progression-free survival (PFS)and overall survival (OS)was 2.7 and 7.3 months.The most common adverse events (AEs)were myelosuppression, nausea,vomit and diarrhea.Conclusion Irinotecan-based combination chemotherapy as second-line regimen is effective,safe and well-tolerated in patients with advanced esophageal squamous cell carcinoma.It is valuable for further observation in clinical practice.